While Biotech Underperformed In The First Half Of 2021, These Names Stood Out With Solid Gains

While biotech stocks underperformed the broader market in the first half of the year, some names – particularly those focused on neurodegenerative diseases and cancer – bucked the trend. In today’s article, the author highlights “a few stocks that stood out with solid gains amid the muted overall sector performance.” For these top biotech gainers in the first half of 2021, CLICK HERE.